NASDAQ:COGT

Cogent Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy COGT

*Your capital is at risk

$32.26

-0.500 (-1.53%)

At Close: Jun 03, 2026

Cogent Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -77.72. In total, the insiders bought 25.9M and sold 12.03M COGT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-77.72
● Buy	25.9M shares
● Sell	12.03M shares
86% Buy Activity Strong Negative Correlation
Sell Signal High Confidence Mar 31, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -77.72. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 17, 2025 Sell	Common Stock F-InKind	Robbins Andrew R President And CEO	CEO / President	367 497 Value: $14.5M
Dec 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Robbins Andrew R President And CEO	CEO / President	245 000 Value: $9.67M
Dec 17, 2025 Sell	Common Stock F-InKind	Pinnow Cole Chief Commercial Officer	Officer	94 800 Value: $3.74M
Dec 17, 2025 Buy	Common Stock A-Award	Pinnow Cole Chief Commercial Officer	Officer	50 000 Value: $1.97M
Dec 17, 2025 Sell	Common Stock F-InKind	Kearns Evan Chief Legal Officer	Officer	125 602 Value: $4.95M
Dec 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Kearns Evan Chief Legal Officer	Officer	55 000 Value: $2.17M
Dec 17, 2025 Sell	Common Stock F-InKind	Sachs Jessica Chief Medical Officer	Officer	154 716 Value: $6.10M
Dec 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Sachs Jessica Chief Medical Officer	Officer	65 000 Value: $2.56M
Dec 17, 2025 Buy	Common Stock A-Award	Sachs Jessica Chief Medical Officer	Officer	50 000 Value: $1.97M
Dec 17, 2025 Buy	Common Stock A-Award	Green John L. Chief Financial Officer	C-Suite Officer	300 000 Value: $11.8M
Dec 17, 2025 Sell	Common Stock F-InKind	Green John L. Chief Financial Officer	C-Suite Officer	145 007 Value: $5.72M
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	1 642 Value: $23.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	1 642 Value: $23.2K
Jul 10, 2025 Buy	Common Stock P-Purchase	Fairmount Funds Management Llc Director	Director	2 777 777 Value: $25.0M
Jul 10, 2025 Buy	Common Stock P-Purchase	Fairmount Funds Management Llc Director	Director	2 777 777 Value: $25.0M
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	3 314 Value: $23.9K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	3 314 Value: $23.9K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Cain Christopher W. Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Ros Matthew Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Shegog Todd Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Harwin Peter Evan Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Morris Arlene Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Morris Arlene Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Harwin Peter Evan Director	Director	44 700 Value: $252.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COGENT BIOSCIENCES, INC.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon ...

Read Full Profile Here